Blavatnik Gift Will Fund Research into the Biology of Survival
Medzhitov and his research team are working to uncover the mechanisms underlying survival strategies—also known as maintenance programs—an endeavor that will both advance fundamental biology and provide new therapeutic targets to prevent and treat disease.
Genome screen uncovers new targets for cancer immunotherapy
A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates to unleash the immune system’s ability to attack a variety of tumor types, Yale Cancer Center researchers report Aug. 22 in the journal Cell.
Iwasaki Is Honored by the International Cytokine & Interferon Society
Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Profesor of Immunobiology and Molecular, Cellular, and Developmental Biology; and professor of dermatology, is a 2019 recipient of the Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research, given by the International Cytokine & Interferon Society (ICIS).
Yale Cancer Center Scientists Advise Caution in Immunotherapy Research
In a new study, Yale Cancer Center scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology of these new therapeutic targets.
Cancer Center Receives Two-pronged Gift
Christine Moog and Benoit Helluy are supporting the new Yale Center for Immuno-Oncology and Yale Cancer Center’s art therapy program. They see their gift as a way both to propel the science in an area where exciting new cancer treatments appear ready to emerge, and to make battling cancer a less-stressful challenge for patients and their loved ones.
Yale Study Shows Immunotherapy Drug Helps Patients with Metastatic Melanoma
When melanoma turns metastatic, it spreads to the brain in more than 40% of patients. A study by Yale Cancer Center researchers published today in the Journal of Clinical Oncology (JCO) shows a checkpoint inhibitor immunotherapy drug has meaningful benefit for these patients. The study is one of the first clinical trials aimed at treating the brain metastases with this type of cancer drug.
Hafler Is Elected to the National Academy of Medicine
David A. Hafler, MD, chair of the Department of Neurology, the William S. and Lois Stiles Edgerly Professor of Neurology, and professor of immunobiology, has been elected to the National Academy of Medicine, in recognition of his outstanding achievements in medicine.
With new genes and an electric shock, scientists turn immune cells against cancer
A promising new class of cancer treatments recruits the cells in our blood to fight tumors, using powerful gene-editing tools to transform a type of white blood cell — called a T cell — from an immune cell that normally targets bacterial or fungal infections into a living cancer drug. The genetic alterations could boost immune systems to successfully fight cancers on their own. Researchers remove T cells from patients and slip new genes into the cells. After clinicians return the modified T cells to patients, the cells, like microscopic bloodhounds, lead the immune system on the hunt for tumors.
New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said. However, patients receiving the therapies are older than those in the clinical trials used to evaluate them, pointing to a disconnect between research and practice that should be addressed, they noted.
Four Faculty Members Elected to the National Academy of Sciences
In recognition of their outstanding research achievements, four faculty members from the School of Medicine have been elected to the National Academy of Sciences (NAS). Akiko Iwasaki, PhD; Haifan Lin, PhD; David G. Schatz, PhD; and Günter Paul Wagner, PhD, were selected for one of the world’s highest honors that can be bestowed on a scientist.
Yale Cancer Center launches Immuno-Oncology Center
Yale Cancer Center (YCC) has launched the Yale Center for Immuno-Oncology (YCIO). The new center will build on YCC’s international leadership in immunobiology, cancer immunology, and development of novel cancer immunotherapies. It is a partnership between YCC and the department of Immunobiology at Yale University.
Bristol-Myers Squibb Announces Expansion of the International Immuno-Oncology Network (II-ON) with Addition of Yale Cancer Center
Bristol-Myers Squibb Company today announced that Yale Cancer Center has joined the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to advance translational Immuno-Oncology (I-O) science. Formed in 2012 by Bristol-Myers Squibb, the II-ON was one of the first networks to bring academia and industry together to further the scientific understanding of I-O, and has since expanded from 10 to 16 sites across North America, Europe, Japan and Australia. Today, the partners collaborate to generate innovative I-O science, launch biology-driven trials and apply cutting-edge technologies with the goal of translating research findings into clinical trials and, ultimately, supporting efforts to improve survival outcomes across tumor types.